CRISPR Therapeutics AG, CRSP
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
Zacks.com on MSN18h
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue EstimatesCRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback